

Primary Bladder Lymphoma: Case Report

Primer Mesane Lenfoması: Olgu Sunumu

Mehmet Sevim¹, Bekir Aras², Şahin Kabay³

¹ Viranşehir State Hospital, Department of Urology, Şanlıurfa

² Kütahya Sağlık Bilimleri University Faculty of Medicine Department of Urology, Kütahya

³ Altınbaş University Faculty of Medicine Department of Urology, İstanbul



Geliş tarihi (Submitted): 16.08.2019

Kabul tarihi (Accepted): 11.12.2019

Yazışma / Correspondence

Mehmet Sevim

Viranşehir State Hospital, Department of Urology, Şanlıurfa, Turkey
Phone Number: 0506 225 5125
E-mail: drmehmetsevim@gmail.com

ORCID

M.S. 0000-0002-7571-7669

B.A. 0000-0002-7020-8830

Ş.K. 0000-0002-4657-9818



Bu eser [Creative Commons Atıf-GayriTicari 4.0](https://creativecommons.org/licenses/by-nc/4.0/) Uluslararası Lisansı ile lisanslanmıştır.

Özet

Mesane karsinomu üriner sistemin en sık görülen tümörüdür. Malign mesane kanserlerinin % 90'dan fazlası, transizyonel hücreli tümörlerdir. Mesanenin transizyonel olmayan tümörleri tüm mesane tümörlerinin %5-7'sini oluşturur. Bunların da yaklaşık %3'ü skuamöz hücreli karsinom, %2'si adenokarsinom, %1'i undiferansiye karsinom ve daha nadiren küçük hücreli karsinom ve lenfomadır. Mesanenin primer lenfoması çok nadir görülür. Nadir olmasına rağmen, bu tümörler ürologlar tarafından akıldta tutulmalı ve sıradışı mesane kitlelerinde düşünülmelidir. Bu yazıda mesane tümörü ön tanısı ile ameliyat edilen primer mesane lenfoması olgusunu sunuyoruz.

Anahtar Kelimeler: Marjinal zon lenfoması, Mesane kanseri, Pozitron emisyon tomografisi

Abstract

Bladder carcinoma is the most common tumor of the urinary system. More than 90 % of malignant bladder cancers are transitional cell tumors. Non-transitional tumors of the bladder account for 5-7 % of all bladder tumors; 3 % squamous cell carcinoma, 2 % adenocarcinoma, 1 % undifferentiated carcinoma and, more rarely, small cell carcinomas and lymphoma. Primary lymphoma of the bladder is very rare. Although rare these tumors should be kept in mind by urologists and should be considered in unusual bladder masses. In this article, we present a case of primary bladder lymphoma who was operated with a preliminary diagnosis of bladder tumor.

Keywords: Marginal zone lymphoma, Bladder cancer, Positron emission tomography

INTRODUCTION

Bladder carcinoma is the most common tumor of the urinary system. More than 90 % of malignant bladder cancers are transitional cell tumors. Non-transitional tumors of the bladder cancer account for 5-7 % of all bladder tumors; 3 % squamous cell carcinoma, 2 % adenocarcinoma, 1 % indifferntiated carcinoma and, more rarely, small cell carcinomas and lymphoma (1). Primary bladder lymphoma is very rare. Publications on this subject are mostly reported as case reports. Lymphomas rarely involve the bladder extranodally and are more common in older women (2). Malignant lymphomas may involve the lower urinary tract in advanced cases but rarely begin primarily from this region. In this article, a case who was operated in our clinic with a preliminary diagnosis of bladder tumor and diagnosed as primary bladder lymphoma after pathological and radiological examination is presented.

CASE REPORT

86 years old male who had operated with transurethral resection 2 years ago because of benign prostatic hyperplasia and last 1 months increased complaints of urinary frequency, nocturia, and significant difficulties initiating a stream, was admitted to our hospital. On our physical examination, the general condition was presented normal and digital rectal exam ++ soft consistency adenoma. Other system examinations were also normal. There was microscopic hematuria in urine test. In the urinary ultrasonography 2 pieces of neoplasms, each one approximately 10x10 mm size with irregular margins and papillo-solid formation was reported posterior wall of the bladder. In this situation cystoscopy was done to our patient. During cystoscopy, on the posterior wall of the bladder 2 pieces of neoplasms were detected. Each one was approximately 10x10 mm size with irregular margins and papillo-solid formation. Also a pathological area, suggesting carcinoma in situ, was observed in a hyperemic, erythematous area of approximately 20x20 mm. Transurethral resection was performed to these tumoral formations. Pathological examination of the transurethral resection material was reported squamous epithelial meta-




Figure 1: Atypical lymphoid cells under transitional surface epithelium (H&E X200)




Figure 2: Atypical lymphoid cells under transitional surface epithelium (H&E X400)

plasia, mild to moderate dysplasia and glandular metaplastic changes (Brunn islands, cystitis cystica). Due to the findings chronic cystitis was diagnosed and also no evidence of invasive malignancy.

In the post-operative 3rd month cystoscopy the resection scars which are right around the orifice and the posterior wall of bladder were viewed. And also erythematous mucosa suggested that precancerous lesions which are on the posterior of trigon were viewed. From this area 10 mm lesion resected for biopsy and pathological examination. After that these lesions were fulgurated. Immunohistochemical evaluation of pathological material showed CD20 (+), CD3 (+) and diffuse CD5 (+) staining and small cell lymphocytic lymphoma can not be ruled out. Pathological speci-

men was consulted again. The immunohistochemical expression of CD20 (+) and bcl (+) were showed and after that extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) was diagnosed (Figure 1 and 2).

The patient's serum levels of urea, creatinine and electrolytes were normal, as was her peripheral blood test. In addition, at computed tomography of the chest and abdomen, multiple number of lymphadenopathies (bilateral cervical region the largest one 15x 8 mm, para-aortic area the largest one 13x12 mm and bilateral inguinal region 15x12 mm) were observed. Then, the whole body PET-CT (Positron Emission Tomography) scan study (to determine this lymphadenomegalies nature and other involvement areas) viewed hypermetabolic bilateral hilar, interlobar, and lobar regions and abdomen, celiac, paraaortic, retrocaval, mesenteric nodes but FDG (fluorodeoxyglucose) uptake was not showed. Then the patient was consulted with radiation oncology and 4 cycles of radiotherapy with a total of 30 Gy were applied. No recurrence was observed in the routine control cystoscopies performed in the following 2 years. Patient died of heart attack after 2 years.

DISCUSSION

Bladder carcinoma is the most common tumor of the urinary system. When it comes to the overall incidence of cancer, it ranks 7th among males and 17th among females (3). More than 90 % of malignant bladder cancers are transitional cell tumors. Non-transitional tumors of the bladder account for 5-7 % of all bladder tumors; 3 % squamous cell carcinoma, 2 % adenocarcinoma, 1 % indifferiated carcinoma and, more rarely, small cell carcinomas and lymphoma (1). Although the bladder is secondarily involved in 10–20% of terminal non-Hodgkin's lymphoma cases, primary lymphomas of the bladder are very uncommon and represent less than 1% of vesical tumors and less than 0.2 % of extranodal lymphomas (4,5). The most common sites of primary extranodal malignant lymphoma are the stomach, connective tissues and skin (6).

If a high-grade lymphoma of the bladder is diagnosed by pathological examination, systemic lympho-

ma should be excluded via clinical and radiographic examinations, including CT of the abdomen and chest. In our case radiological and pathological examinations of our patient caused the diagnosis of primary bladder lymphoma.

Primary lymphoma of the urinary bladder is very rare, with MALT lymphoma being the most common type lymphomas (7). The first case report of MALT lymphoma of the urinary bladder was described by Kuhara et al. in 1990 (5). The etiology of primary lymphoma of the bladder has not been elucidated, partly because of the rarity of the condition. While a study indicates that history of chronic cystitis was reported in 20% of cases and it usually affects female patients (8) in another study it was reported that 2/3 of these tumours which was thought to be originated from chronic inflammation was developed in chronic cystitis background (9). As stated in literature; cystitis cystica was also determined in first pathology in our case and at the 3. month pathology transformation to MALT lymphoma was monitored. There is no naturally occurring lymphoid tissue in the bladder, so one explanation for MALT pathogenesis at this site is that repetitive recurrent infection results in the accumulation of extranodal lymphoid tissue that can eventually undergo malignant alteration (10). The most effective therapeutic procedure for primary MALT lymphoma of the urinary bladder is still debated. Increasing evidence indicates that eradication of *Helicobacter pylori* with antibiotics can be effectively used as the sole initial treatment for gastric MALT (11). Localized gastric MALT lymphoma was previously treated mainly by surgery and radiotherapy (12). Unfortunately, no specific treatment has been identified for non-gastric location of MALT lymphoma. The treatment of non-gastric MALT consists of radiotherapy if the disease is localized, or chemotherapy if disseminated (13).

As stated in literature chemotherapy was planned for our patient but because of patient's age and comorbidities chemotherapy was cancelled and local radiotherapy applied after transurethral resection. It is reported that primary bladder lymphoma starts in the trigone zone of bladder and diffuse wall involvement

ratio is %3. It is also reported Non-hodgkin lymphoma (NHL) is originated from submucosal lymph follicles of bladder and the most common type of NHL is diffuse big cell lymphoma (14). In the study of Simpson et al. determined primary lymphoma of bladder only 2 of 68 NHL patient and reported disuria and hematuria are the most common symptoms (15). Bates et al evaluated 11 patients who has bladder lymphoma. 6 of them was primary bladder lymphoma. They reported that 3 of 6 primary bladder lymphoma patients were MALT (mucosa associated lymphoid tissue) and the other 3 were diffuse big B cell lymphoma (4). In the study of Al-Magrabi et al 4 primary bladder lymphoma patient were evaluated, all of four were older than 60 and had history of chronic cystitis. Patients were treated with only radiotherapy and reported that all of four patient had complete remission 2 year to 13 year follow up (16). In our case; patient was diagnosed marginal zone lymphoma pathologically after transurethral resection procedure and used PET-CT to determine possible other involvement regions and designate the nature of lymph node seen in the PET-CT (FDG-PET) scan using fluorodeoxyglucose is highly beneficial to diagnose and treatment of several malignancies including lymphomas. Hodgkin lymphomas and aggressive non-Hodgkin lymphomas (typically diffuse B cell lymphoma) usually usually show high FDG uptake. It is reported that FDG-PET is more sensitive in B cell lymphomas as seen this case. (17). Appropriate doses of radiotherapy treatment has perfect results on prognosis of localised malt lymphomas (18). As mentioned in the several studies; in this case report we also have implemented radiotherapy treatment in the patient and as a result of 1 month therapy disease has become clinically remitted.

As a result; primary lymphoma of bladder is very rare comparing to other urethelial bladder cancers and and it is more common specially in women and older ages. It is necessary to examine systematically to distinguish from seconder lymphomas which has bladder involvement for the diagnose of primary lymphoma of bladder. Most common symptom is disuria and also hematuria as seen in the other types of bladder can-

cers. There is no consensus regarding the treatment of primary lymphoma of the bladder, owing to the lack of large patient series. Well responded to chemotherapy and radiotherapy. It differentiates from other types of rethial bladder tumours by fully remission rates and very good prognosis.

Ethical Approval

Not applicable.

Sources of Funding

None declared.

Conflicts of Interest

None declared. The authors have no financial, consultative, institutional, and other relationships that might lead to bias or conflict of interest.

REFERENCES

1. Fortuny J, Kogevinas M, Chang-Claude J, et al. Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. *Int J Cancer* 1999;80:44-6.
2. Manunta A, Vincendeau S, Kirikakou G, et al. Non-transitional cell bladder carcinomas. *BJU international* 2005;95:497-502.
3. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. *Int J Cancer* 2013;132:1133-45.
4. Bates AW et al. Malignant lymphoma of the urinary bladder: a clinicopathological study of 11 cases. *J Clin Pathol* 2000;53:458-461.
5. Kuhara H, Tamura Z, Suchi T, et al. Primary malignant lymphoma of the urinary bladder: A case report. *Acta Pathol Jpn* 1990;40: 764-769.
6. Horasanli, Kaya, et al. A case of primary lymphoma of the bladder managed with multimodal therapy. *Nature Reviews Urology* 2008;5:167.
7. Hughes M, Morrison A and Jackson R Primary bladder lymphoma: Management and outcome of 12 patients with a review of the literature. *Leuk Lymphoma* 2005;46: 873-877.
8. Ohsawa M, Aozasa K, Horiuchi K, et al. Malignant lymphoma of bladder. Report of three cases and review of the literature. *Cancer* 1993;72:1969-74.
9. Kempton CL, Kurtin PJ, Inwards DJ, et al. Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. *Am J Surg Pathol* 1997;21:1324.
10. Oscier D, Bramble J, Hodges E, et al. Regression of mucosa-

- associated lymphoid tissue lymphoma of the bladder after antibiotic therapy. *J Clin Oncol* 2000;20:882.
11. Montalban C, Santon A, Boixeda D, Redondo et al. Treatment of low-grade gastric mucosa associated lymphoid tissue lymphoma in stage I with *Helicobacter pylori* eradication: Long-term results after sequential histologic and molecular follow-up. *Haematologica* 2001;86:609-617.
 12. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to *Helicobacter pylori* eradication therapy. *Lancet* 2001;357:39-40.
 13. Raderer M, Wohrer S, Bartsch R, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. *J Clin Oncol* 2005;23: 8442-8446.
 14. National Cancer Institute sponsored study of classifications of non-hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. *Cancer* 1982;49:2112-35.
 15. Simpson RHW, Bridger JE, Anthony PP, et al: Malignant lymphoma of the lower urinary tract: A clinicopathologic study with review of literature. *Br J Urol* 1990;65:254-60.
 16. Al-Maghrabi J, Kamel Reid S, Jewett M, et al: Primary low grade B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT). *Arch Pathol Lab Med* 2001;125: 332-36.
 17. Elstrom R, Guan L, Baker G: Utility of FDG-PET scanning in lymphoma by WHO classification, *Blood* 2003;101:3875-3876.
 18. Tsang RW1, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. *Int J Radiat Oncol Biol Phys* 2001;5:1258-64.